Guggenheim initiated coverage on shares of Novogen (NASDAQ:KZIA – Free Report) in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $35.00 price objective on the stock.
Several other analysts have also recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $40.00 price objective on shares of Novogen in a research note on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a report on Thursday, October 15th. Canaccord Genuity Group assumed coverage on shares of Novogen in a report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Finally, Leerink Partners initiated coverage on shares of Novogen in a research note on Tuesday. They issued an “outperform” rating and a $30.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.
Check Out Our Latest Report on Novogen
Novogen Trading Down 3.2%
Shares of Novogen stock opened at $7.81 on Wednesday. Novogen has a 12-month low of $4.86 and a 12-month high of $17.40. The company has a 50-day simple moving average of $10.76 and a 200 day simple moving average of $11.97.
About Novogen
Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.
Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.
In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.
Recommended Stories
- Five stocks we like better than Novogen
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
